FibroGen, Inc. (NASDAQ:FGEN) This autumn 2024 Earnings Convention Name March 17, 2025 5:00 PM ET
Firm Individuals
Joanne Greller – LifeSci AdvisorsThane Wettig – CEODavid DeLucia – CFO
Convention Name Individuals
Andy Sieh – William BlairMatthew Keller – H.C. Wainwright
Operator
Good day everybody, and welcome to the FibroGen Fourth Quarter and Full 12 months 2024 Earnings Convention Name. At the moment, all individuals are in a listen-only mode. After the speaker’s presentation, there might be a question-and-answer session. [Operator Instructions] Please be suggested that in the present day’s convention, is being recorded.
Now, it is my pleasure to show the decision over to, Joanne Greller. The ground is yours.
Joanne Greller
Thanks, operator. Good afternoon, everybody. Thanks for becoming a member of in the present day, to debate FibroGen’s fourth quarter and full 12 months 2024 monetary and enterprise outcomes. I am Joanne Greller from LifeSci Advisors. Becoming a member of me on in the present day’s name are Thane Wettig, our Chief Govt Officer and David DeLucia, our Chief Monetary Officer. Following our ready remarks, we’ll open the decision to your questions.
I wish to remind you that remarks made on in the present day’s name embody forward-looking statements about FibroGen. Such statements might embody, however usually are not restricted to our collaborations with AstraZeneca and Astellas; monetary steering; the initiation, enrollment, design, conduct and outcomes of medical trials; our regulatory methods and potential regulatory outcomes; our analysis and growth actions; industrial outcomes and outcomes of operations; dangers associated to our enterprise; and sure different enterprise issues.
Every forward-looking assertion, is topic to dangers and uncertainties that might trigger precise outcomes and occasions to vary materially from these projected in that assertion. A extra full description of those and different materials dangers could be present in FibroGen’s filings with the SEC together with our most up-to-date Type 10-Ok and Type 10-Q.
FibroGen doesn’t undertake any obligation
